RayKnowChina Research Map
Shortlist0

Not yet recruitingStomach cancerPhase 4

Registered title, quoted from ClinicalTrials.gov

Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing

An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFirst Hospital of Lanzhou University兰州大学第一医院LanzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07312370, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. ECOG performance status 0-1

    Inclusion criterion 7

  3. Coagulation disorders (INR >1.5 or platelet count <50×10⁹/L)

    Exclusion criterion 5

  4. Pregnancy or lactation

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07312370, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18-80 years, male or female
  • Diagnosed with early gastric cancer or high-grade intraepithelial neoplasia planned for gastric ESD
  • Lesion location: Gastric corpus, antrum, or angle (cardiac lesions may be included but will require subgroup analysis)
  • Successful en bloc resection achieved by ESD
  • Post-ESD artificial ulcer diameter ≥2 cm
  • Complete coagulation of all visible vessels during ESD procedure
  • ECOG performance status 0-1
  • Able to comply with follow-up visits and endoscopic examinations
  • Voluntary participation with written informed consent

Exclusion Criteria:

  • Previous gastric surgery history
  • Active peptic ulcer disease (confirmed by pre-ESD endoscopy) within 1 month
  • Recent upper gastrointestinal bleeding (within 1 month, excluding tumor-related bleeding)
  • Severe heart, liver, or kidney dysfunction (Child-Pugh class C, NYHA class III-IV, or CKD stage 4-5)
  • Coagulation disorders (INR >1.5 or platelet count <50×10⁹/L)
  • Uncontrolled diabetes (HbA1c >9%)
  • Known allergy or hypersensitivity to PPIs or sucralfate
  • Use of PPIs, H2 receptor antagonists, or mucosal protective agents within 2 weeks prior to ESD
  • Long-term anticoagulant therapy that cannot be discontinued (e.g., warfarin, direct oral anticoagulants)
  • Long-term NSAIDs or aspirin (>100mg/day) that cannot be discontinued
  • Unsuccessful complete (en bloc) resection (piecemeal resection)
  • Intraoperative perforation
  • Uncontrolled active bleeding during ESD
  • Pregnancy or lactation
  • Women of childbearing potential not using adequate contraception
  • Concurrent participation in another clinical trial
  • Any condition that, in the investigator's opinion, makes the patient unsuitable for study participation

Quoted from ClinicalTrials.gov, NCT07312370, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07312370, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07312370